TP53 and prostate adenocarcinoma: This dichotomy is apparent in a wide range of cancers, such as prostate adenocarcinoma, childhood malignant gliomas [15], endometrial carcinoma [16], and laryngeal squamous cell carcinoma [17], where overexpression of TP53 often predicts adverse outcomes.